Key Points

• Research indicates that Bayer has resolved approximately 130,000 Roundup lawsuits through settlements totaling around $11 billion, though outcomes can vary based on individual circumstances.
• Evidence suggests there are still about 65,000 active claims, reflecting the ongoing complexity of these cases.
• It seems likely that the U.S. Supreme Court’s review of federal preemption in the Monsanto v. Durnell case could influence many pending lawsuits, with a decision expected by mid-2026.
• Settlement amounts typically range from $5,000 to $250,000, with averages around $100,000 to $160,000, depending on factors like exposure duration and illness severity.
• Eligibility often involves prolonged exposure to Roundup and a diagnosis of non-Hodgkin lymphoma or related cancers, but individual assessments are needed to confirm.
• Both sides present strong arguments: plaintiffs emphasize health risks, while Bayer highlights regulatory approvals, underscoring the debated nature of glyphosate’s safety.

Current Settlement Status

As of February 2026, Bayer continues to address thousands of claims related to Roundup, the widely used herbicide containing glyphosate. Settlements have provided compensation to many affected individuals, but new cases are still being filed. For those potentially eligible, understanding exposure history and medical diagnoses is key, and consulting professionals can help clarify options without assuming outcomes.

Payouts and Compensation

Payouts in Roundup cases reflect a range of factors, including medical costs, lost wages, and pain and suffering. While some have reached millions in trial verdicts, most settlements fall in the mid-range, offering a balanced resolution for many. It’s important to note that each case is unique, and figures are drawn from public records of past resolutions.

Supreme Court Developments

The Supreme Court’s decision to review a key Roundup case highlights ongoing debates over federal versus state laws on product warnings. This could affect how future claims proceed, but it doesn’t halt current processes. Stakeholders on all sides are watching closely, as the ruling may bring more clarity to this long-standing issue.

Eligibility Considerations

If you’ve used Roundup extensively, such as in farming, landscaping, or gardening and later received a cancer diagnosis like non-Hodgkin lymphoma, you might meet basic eligibility criteria. However, timelines for filing vary by state, and evidence of direct exposure is typically required. This area involves nuance, so approaching it thoughtfully is advisable.

Introduction

The Roundup lawsuit landscape remains a significant area of legal activity in the United States, centering on claims that exposure to the herbicide’s active ingredient, glyphosate, has led to serious health issues, particularly non-Hodgkin lymphoma. As of February 2026, Bayer AG, which acquired Monsanto in 2018, has faced ongoing multidistrict litigation (MDL) and individual state court cases alleging failure to warn consumers about potential cancer risks. This update is timely given recent developments, including the U.S. Supreme Court’s agreement to review a pivotal case that could reshape the litigation.

These lawsuits matter now because they affect thousands of individuals who may have been exposed to Roundup through occupational or residential use. Potential claimants include agricultural workers, landscapers, and homeowners who used the product regularly. The cases highlight broader consumer rights issues under product liability laws, emphasizing the balance between federal regulatory approvals and state-level protections. For those impacted, understanding current settlements, payout structures, and Supreme Court implications is essential for informed decision-making. This article provides factual updates based on court records and regulatory frameworks, but it is for informational purposes only and does not constitute legal advice.

Background & Legal Context

Roundup, developed by Monsanto in the 1970s, became one of the world’s most popular herbicides due to its effectiveness in controlling weeds, especially in conjunction with genetically modified crops. Glyphosate, its primary active ingredient, works by inhibiting an enzyme essential for plant growth. The U.S. Environmental Protection Agency (EPA) has repeatedly approved glyphosate for use, stating in its 2020 interim decision that it poses no risks to human health when used as directed. However, controversy arose in 2015 when the International Agency for Research on Cancer (IARC), part of the World Health Organization, classified glyphosate as “probably carcinogenic to humans” based on limited evidence in humans and sufficient evidence in animals.

This classification spurred a wave of lawsuits starting in 2015, with plaintiffs alleging that Monsanto (and later Bayer) failed to adequately warn users about cancer risks, violating state consumer protection and product liability laws. The litigation consolidated into a federal MDL in the U.S. District Court for the Northern District of California under Judge Vince Chhabria, who has overseen pretrial proceedings, including discovery and bellwether trials. Key precedents include the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), which governs pesticide labeling and requires EPA approval, creating debates over whether federal law preempts state claims.

Prior rulings have been mixed. For instance, in early trials like Hardeman v. Monsanto (2019), juries awarded significant damages, though some were reduced on appeal. Bayer’s acquisition of Monsanto amplified the stakes, leading to a major settlement framework in 2020. Legislative efforts, such as state-level proposals to shield companies from liability if they comply with EPA labels, have also emerged but faced opposition from consumer advocacy groups.

Key Legal Issues Explained

At the core of the Roundup lawsuits is the concept of “failure to warn,” a common claim under state tort law where manufacturers must disclose known risks. Plaintiffs argue that Monsanto knew or should have known about glyphosate’s potential carcinogenicity but omitted warnings from labels, leading to foreseeable harm. In plain terms, this means users were not informed of risks like developing non-Hodgkin lymphoma, a cancer affecting the lymphatic system, after prolonged exposure.

A critical legal principle here is federal preemption under FIFRA. This doctrine holds that if a product’s label complies with federal requirements, states cannot impose additional warning obligations. Bayer contends that EPA approvals, which have consistently found no cancer risk from glyphosate, shield it from state claims. However, courts have split: the Third Circuit Court of Appeals ruled in favor of preemption in Schaffner v. Monsanto (2024), while the Eleventh Circuit in Carson v. Monsanto (2024) held otherwise, allowing state claims to proceed.

Other issues include causation proving that glyphosate directly caused the plaintiff’s cancer, and punitive damages, awarded to punish alleged misconduct. Regulatory frameworks like California’s Proposition 65, which requires cancer warnings for known carcinogens, add layers, as glyphosate was listed in 2017. These concepts underscore the tension between uniform federal regulation and state-specific consumer protections, ensuring companies adhere to safety standards while allowing individuals recourse for harm.

Latest Developments or Case Status

As of February 2026, the Roundup MDL in California reports 3,902 pending cases, down from 4,511 in January, reflecting ongoing resolutions and administrative dismissals. Bayer has resolved approximately 132,000 of 197,000 total claims, with payouts totaling about $11 billion. Recent verdicts include a $78 million award in Philadelphia in October 2024 ($3 million compensatory, $75 million punitive) and a $2.1 billion verdict in Georgia in March 2025. Appeals have reduced some awards, such as a Missouri case affirmed at $611 million in May 2025.

A major development occurred on January 16, 2026, when the U.S. Supreme Court granted certiorari in Monsanto Company v. Durnell, a case stemming from a $1.25 million Missouri verdict. The Court will address whether FIFRA preempts state failure-to-warn claims, potentially resolving circuit splits and limiting future litigation. Briefing and arguments are slated for the 2025-2026 term, with a decision by June 2026. Bayer welcomed the review, viewing it as a step toward containing the litigation.

Financially, Bayer added $1.37 billion to reserves in August 2025 and another $1.1 billion in November 2025 to cover ongoing cases. Settlement programs continue, with Special Master Kenneth Feinberg mediating under court order. In X (formerly Twitter) discussions, stakeholders express concerns over corporate accountability versus regulatory clarity.

This table illustrates the variability in outcomes, with appeals often reducing punitive damages under due process standards from cases like BMW of North America v. Gore (1996).

Who Is Affected & Potential Impact

Primarily affected are individuals with prolonged exposure to Roundup, such as farmers, groundskeepers, and residential users who applied the product without protective gear. Diagnoses often involve non-Hodgkin lymphoma, but some claims include leukemia or multiple myeloma. Businesses like agricultural firms may face indirect impacts through supply chain adjustments if litigation alters product availability.

Potential outcomes include reduced liability for Bayer if the Supreme Court rules in favor of preemption, potentially dismissing thousands of state claims. Conversely, a ruling against could encourage more filings, increasing pressure on companies to enhance warnings. Broader implications affect regulatory trust: if federal approvals override state laws, it could streamline product markets but raise concerns over consumer safety. Institutions like the EPA and state courts continue monitoring, with possible policy shifts emphasizing rigorous testing.

What This Means Going Forward

The Supreme Court’s review carries significant legal weight, potentially clarifying preemption under FIFRA and influencing similar product liability cases beyond pesticides. For the public, it underscores the importance of evidence-based regulation, as ongoing studies by agencies like the EPA reaffirm glyphosate’s safety profile. Industry-wise, Bayer’s shift to non-glyphosate formulations for residential products since 2023 aims to mitigate future risks.

Readers should monitor SCOTUS updates via official dockets and reputable sources like the American Bar Association. Those with potential claims may consider timelines, as statutes of limitations (typically 2-3 years from diagnosis) vary by state. Overall, this litigation highlights evolving standards in consumer protection, encouraging vigilance in product use.

Conclusion

The Roundup lawsuits exemplify the intersection of consumer rights, regulatory oversight, and corporate accountability. With billions in settlements already paid and the Supreme Court’s impending decision, this matter continues to evolve, offering lessons on product safety disclosures. Staying informed through credible sources remains crucial for affected individuals and the public, ensuring balanced perspectives on this public interest issue.

Frequently Asked Questions

What is the average settlement amount in Roundup lawsuits?

Settlement amounts vary, but in the 2020 global framework, averages ranged from $100,000 to $160,000 per claimant, influenced by factors like exposure duration and illness severity. Higher tiers for severe cases can exceed $200,000.

Who is eligible to file a Roundup lawsuit?

Eligibility generally requires documented prolonged exposure to glyphosate-based Roundup and a diagnosis of non-Hodgkin lymphoma or related cancers. Occupational users like landscapers often qualify, but claims must meet state-specific statutes of limitations.

How does the Supreme Court’s review affect existing claims?

The review in Monsanto v. Durnell could dismiss claims if preemption is upheld, but it doesn’t automatically halt ongoing cases. Mediation continues in the MDL.

What are the payout ranges for Roundup settlements?

Payouts typically span $5,000 to $250,000, with some trial verdicts reaching millions before reductions. Factors include medical evidence and jurisdiction.

Has Bayer settled all Roundup lawsuits?

No, approximately 65,000 claims remain unresolved as of late 2025, with settlements covering about 67% of total filings.

What evidence is needed for a Roundup claim?

Key evidence includes medical records linking diagnosis to exposure, purchase or usage history, and expert testimony on causation.

You May Also like: How the FirstEnergy Attorney-Client Privilege Ruling Redefines Legal Boundaries in Ohio